Pharmaceuticals Deals: QCOR Gets a Big Premium, Roche Goes Shopping

Monday's big pharmaceuticals deals included Mallinckrodt buying Questcor for $5.6B -- a 27% premium to QCOR stock -- and Roche picking up Ranbaxy. More 

4 Ways Obamacare Will Affect Stocks

Obamacare is here to stay. That's good for some stocks, and horrible for others. Here's a look at the winners and losers. More 

INSM: Insmed Stock Sinks on Study Fail

Insmed announced that a Phase II study of a leading product candidate failed to meet its primary goals, sending INSM stock down sharply. More 

SNTA: Synta Pharmaceuticals Soars on Breast Cancer Treatment News

Synta Pharmaceuticals reported positive interim results from a study of its breast cancer drug, sending SNTA stock up sharply. More 

OXGN: OXiGENE Stock Soars on Ovarian Cancer Study Results

After OXiGENE announced favorable results from a Phase 2 clinical drug trial, OXGN shares doubled in value. More 

Purdue’s Pill Success Is Bad News for Zogenix Zohydro, ZGNX Stock

Purdue Pharma's plans to pursue FDA approval of its back-pain medication could mean the end of a Zogenix drug, sending ZGNX stock plunging. More 

IDIX: Idenix Pharmaceuticals Up 17% on No News

Indenix Pharmaceuticals stock shot up in pre-market trading on Monday, but IDIX shares cooled significantly in morning trading on a lack of news. More